{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:55:34Z","timestamp":1790074534602,"version":"4.0.1"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00107","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T06:34:34Z","timestamp":1551422074000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets"],"prefix":"10.3389","volume":"9","author":[{"given":"Yi","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun Y.","family":"Xu-Monette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ctrv.2018.01.002","article-title":"Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma","volume":"65","author":"Dunleavy","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Gutierrez-Garcia","year":"2011","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470\u20132045(11)70235\u20132","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470\u20132045(08)70002\u20130","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/cancers7020812","article-title":"Insights into the molecular pathogenesis of activated B-cell-like diffuse large B-Cell lymphoma and its therapeutic implications","volume":"7","author":"Lenz","year":"2015","journal-title":"Cancers."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.beha.2012.01.003","article-title":"New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma","volume":"25","author":"Frick","year":"2012","journal-title":"Best Pract Res Clin Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cell.2004.05.014","article-title":"Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha\/beta heterodimer","volume":"117","author":"Kraus","year":"2004","journal-title":"Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell."},{"key":"B13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature."},{"key":"B14","doi-asserted-by":"publisher","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens","volume":"112","author":"Young","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/gcc.22126","article-title":"Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma","volume":"53","author":"Bohers","year":"2014","journal-title":"Genes Chromosomes Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8240","DOI":"10.1021\/bi101052d","article-title":"Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain","volume":"49","author":"Lamason","year":"2010","journal-title":"Biochemistry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1084\/jem.20180230","article-title":"Activated CARD11 accelerates germinal center kinetics, promoting mTORC1 and terminal differentiation","volume":"215","author":"Wray-Dutra","year":"2018","journal-title":"J Exp Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/blood-2007\u201307-100115","article-title":"SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma","volume":"111","author":"Chen","year":"2008","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2016\u201310-747303","article-title":"Tonic B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"130","author":"Havranek","year":"2017","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008\u20135472.CAN-18\u20130215","article-title":"MYD88 L265P mutation in lymphoid malignancies","volume":"78","author":"Yu","year":"2018","journal-title":"Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3389\/fimmu.2016.00390","article-title":"The role of toll-like receptors in hematopoietic malignancies","volume":"7","author":"Monlish","year":"2016","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2014\u201305-573188","article-title":"Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization","volume":"124","author":"Avbelj","year":"2014","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/blood-2015\u201311-684183","article-title":"B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice","volume":"127","author":"Knittel","year":"2016","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1084\/jem.20161454","article-title":"Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM","volume":"214","author":"Wang","year":"2017","journal-title":"J Exp Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586\u2013018-0290\u20130","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature."},{"key":"B29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Cory","year":"2002","journal-title":"Nat Rev Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012\u201310-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP consortium program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/349254a0","article-title":"Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18)","volume":"349","author":"McDonnell","year":"1991","journal-title":"Nature."},{"key":"B33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0092\u20138674(89)90174\u20138","article-title":"bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation","volume":"57","author":"McDonnell","year":"1989","journal-title":"Cell."},{"key":"B34","doi-asserted-by":"publisher","first-page":"11376","DOI":"10.1073\/pnas.89.23.11376","article-title":"Differential effects of Bcl-2 on T and B cells in transgenic mice","volume":"89","author":"Katsumata","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical impact of the cell-of-origin classification and the MYC\/ BCL2 dual expresser status in diffuse large b-cell lymphoma treated within prospective clinical trials of the german high-grade non-hodgkin's lymphoma study group","volume":"35","author":"Staiger","year":"2017","journal-title":"J Clin Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Visco","year":"2013","journal-title":"Haematologica."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/01.pas.0000167362.06148.95","article-title":"Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a \u201cnon-germinal center phenotype\u201d","volume":"29","author":"Kusumoto","year":"2005","journal-title":"Am J Surg Pathol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"11294","DOI":"10.1073\/pnas.0903854106","article-title":"BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma","volume":"106","author":"Saito","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/leu.2014.351","article-title":"MicroRNAs in B-cell lymphomas: how a complex biology gets more complex","volume":"29","author":"Musilova","year":"2015","journal-title":"Leukemia."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1128\/MCB.01647\u201305","article-title":"Bcl2's flexible loop domain regulates p53 binding and survival","volume":"26","author":"Deng","year":"2006","journal-title":"Mol Cell Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/leu.2011.378","article-title":"BCL2 mutations in diffuse large B-cell lymphoma","volume":"26","author":"Schuetz","year":"2012","journal-title":"Leukemia."},{"key":"B42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/cdd.2011.97","article-title":"Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl","volume":"19","author":"Monaco","year":"2012","journal-title":"Cell Death Differ."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/leu.2012.367","article-title":"MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma","volume":"27","author":"Wenzel","year":"2013","journal-title":"Leukemia."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1182\/blood.V97.12.3902","article-title":"MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes","volume":"97","author":"Zhou","year":"2001","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1172\/JCI89486","article-title":"BCL-W has a fundamental role in B cell survival and lymphomagenesis","volume":"127","author":"Adams","year":"2017","journal-title":"J Clin Invest."},{"key":"B46","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1158\/1078\u20130432.CCR-17\u20131144","article-title":"Non-Hodgkin and hodgkin lymphomas select for overexpression of BCLW","volume":"23","author":"Adams","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/cncr.22219","article-title":"Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas","volume":"107","author":"Akyurek","year":"2006","journal-title":"Cancer."},{"key":"B48","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/path.2747","article-title":"Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling","volume":"222","author":"Hussain","year":"2010","journal-title":"J Pathol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/modpathol.2015.94","article-title":"Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy","volume":"28","author":"Liu","year":"2015","journal-title":"Modern Pathol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/362857a0","article-title":"Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53","volume":"362","author":"Oliner","year":"1993","journal-title":"Nature."},{"key":"B51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s000180050273","article-title":"Functions of the MDM2 oncoprotein","volume":"55","author":"Freedman","year":"1999","journal-title":"Cell Mol Life Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012\u201305-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL Rituximab-CHOP consortium program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","article-title":"Modeling the therapeutic efficacy of p53 restoration in tumors","volume":"127","author":"Martins","year":"2006","journal-title":"Cell."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/ijc.30838","article-title":"TP53 mutation and survival in aggressive B cell lymphoma","volume":"141","author":"Zenz","year":"2017","journal-title":"Int J Cancer."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2009-10-247122","article-title":"Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study","volume":"116","author":"Jardin","year":"2010","journal-title":"Blood."},{"key":"B56","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nature03147","article-title":"The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells","volume":"432","author":"Phan","year":"2004","journal-title":"Nature."},{"key":"B57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ccr.2012.07.014","article-title":"Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma","volume":"22","author":"Monti","year":"2012","journal-title":"Cancer Cell."},{"key":"B58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0092-8674(00)81401-4","article-title":"ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways","volume":"92","author":"Zhang","year":"1998","journal-title":"Cell."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1101\/gad.511109","article-title":"Histone demethylase JMJD3 contributes to epigenetic control of INK4a\/ARF by oncogenic RAS","volume":"23","author":"Barradas","year":"2009","journal-title":"Genes Dev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e18421","DOI":"10.1371\/journal.pone.0018421","article-title":"p53 interaction with JMJD3 results in its nuclear distribution during mouse neural stem cell differentiation","volume":"6","author":"Sola","year":"2011","journal-title":"PLoS ONE."},{"key":"B61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cell.2005.07.034","article-title":"Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin","volume":"123","author":"Takagi","year":"2005","journal-title":"Cell."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1046\/j.1432\u20131327.2001.02226.x","article-title":"p300\/CBP\/p53 interaction and regulation of the p53 response","volume":"268","author":"Grossman","year":"2001","journal-title":"Eur J Biochem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature."},{"key":"B64","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood.V69.5.1307.bloodjournal6951307","article-title":"The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor","volume":"69","author":"Tweeddale","year":"1987","journal-title":"Blood."},{"key":"B65","doi-asserted-by":"publisher","first-page":"92289","DOI":"10.18632\/oncotarget.21241","article-title":"The prognostic significance of CD11b(+)CX3CR1(+) monocytes in patients with newly diagnosed diffuse large B-cell lymphoma","volume":"8","author":"Yhim","year":"2017","journal-title":"Oncotarget."},{"key":"B66","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/PAS.0000000000000851","article-title":"Tumor Microenvironment and checkpoint molecules in primary cutaneous diffuse large b-cell lymphoma-new therapeutic targets","volume":"41","author":"Mitteldorf","year":"2017","journal-title":"Am J Surg Pathol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3109\/10428194.2013.879713","article-title":"An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","volume":"55","author":"Nam","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s12032\u2013011-0123\u20136","article-title":"High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma","volume":"29","author":"Cai","year":"2012","journal-title":"Med Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"16471","DOI":"10.18632\/oncotarget.4106","article-title":"Neutrophils trigger a NF-kappaB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas","volume":"6","author":"Gregoire","year":"2015","journal-title":"Oncotarget."},{"key":"B70","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1073\/blood-2006\u201302-001800","article-title":"Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness","volume":"109","author":"Schwaller","year":"2007","journal-title":"Blood."},{"key":"B71","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1158\/0008\u20135472.CAN-16\u20130786","article-title":"CXCL-8\/IL8 produced by diffuse large b-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL","volume":"77","author":"Manfroi","year":"2017","journal-title":"Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1226","article-title":"Neutrophil extracellular traps induced by IL-8 promote diffuse large B cell lymphoma progression via the TLR9 signaling","author":"Nie","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000488385","article-title":"Highly Tumorigenic diffuse large b cell lymphoma cells are produced by coculture with stromal cells","volume":"139","author":"Lin","year":"2018","journal-title":"Acta Haematol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/sj.leu.2404723","article-title":"Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB\/p52) in non-Hodgkin's lymphoma cells","volume":"21","author":"Lwin","year":"2007","journal-title":"Leukemia."},{"key":"B76","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nm1614","article-title":"Essential role of stromally induced hedgehog signaling in B-cell malignancies","volume":"13","author":"Dierks","year":"2007","journal-title":"Nat Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1038\/onc.2011.195","article-title":"ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma","volume":"30","author":"Singh","year":"2011","journal-title":"Oncogene."},{"key":"B78","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.humpath.2005.09.016","article-title":"CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas","volume":"37","author":"Marmey","year":"2006","journal-title":"Hum Pathol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1189\/jlb.0706481","article-title":"Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation","volume":"82","author":"Mueller","year":"2007","journal-title":"J Leukoc Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.yexcr.2016.11.017","article-title":"Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway","volume":"350","author":"Cha","year":"2017","journal-title":"Exp Cell Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978\u20133-319\u201322822-8_13","article-title":"The role of EBV in the pathogenesis of diffuse large b cell lymphoma","volume":"390","author":"Healy","year":"2015","journal-title":"Curr Top Microbiol Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2015\u201302-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood."},{"key":"B83","doi-asserted-by":"publisher","first-page":"9150","DOI":"10.1073\/pnas.90.19.9150","article-title":"Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation","volume":"90","author":"Kaye","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B84","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1126\/science.286.5438.300","article-title":"Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses","volume":"286","author":"Uchida","year":"1999","journal-title":"Science."},{"key":"B85","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1006\/scbi.2001.0410","article-title":"LMP1 structure and signal transduction","volume":"11","author":"Eliopoulos","year":"2001","journal-title":"Semin Cancer Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.1038\/sj.onc.1208846","article-title":"Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K","volume":"24","author":"Mainou","year":"2005","journal-title":"Oncogene."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1128\/JVI.01888\u201307","article-title":"Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway","volume":"82","author":"Dawson","year":"2008","journal-title":"J Virol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2217\/fon.09.53","article-title":"Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma","volume":"5","author":"Morris","year":"2009","journal-title":"Future Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1128\/JVI.76.1.455\u2013459.2002","article-title":"The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines","volume":"76","author":"Higuchi","year":"2002","journal-title":"J Virol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/0092\u20138674(91)90007-L","article-title":"Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death","volume":"65","author":"Henderson","year":"1991","journal-title":"Cell."},{"key":"B91","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2013\u201303-489708","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"122","author":"Ok","year":"2013","journal-title":"Blood."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/path.5237","article-title":"Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC subtype diffuse large B cell lymphoma","author":"Vockerodt","year":"2019","journal-title":"J Pathol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e22509","DOI":"10.7554\/eLife.22509","article-title":"Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection","volume":"6","author":"Price","year":"2017","journal-title":"Elife."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1084\/jem.20072581","article-title":"An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival","volume":"205","author":"Choy","year":"2008","journal-title":"J Exp Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.virol.2011.01.028","article-title":"The epstein-barr virus BART microRNAs target the pro-apoptotic protein Bim","volume":"412","author":"Marquitz","year":"2011","journal-title":"Virology."},{"key":"B96","doi-asserted-by":"publisher","first-page":"14304","DOI":"10.3390\/molecules190914304","article-title":"Inhibition of the PI3K\/Akt\/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance","volume":"19","author":"Majchrzak","year":"2014","journal-title":"Molecules."},{"key":"B97","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S1470\u20132045(14)70311\u20130","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/blood-2017\u201308-802561","article-title":"A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL","volume":"131","author":"Sauter","year":"2018","journal-title":"Blood."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.18632\/oncotarget.794","article-title":"Attacking MALT1 for ABC-DLBCL therapy","volume":"3","author":"Krappmann","year":"2012","journal-title":"Oncotarget."},{"key":"B101","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ccr.2012.11.002","article-title":"Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL","volume":"22","author":"Nagel","year":"2012","journal-title":"Cancer Cell."},{"key":"B102","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ccr.2012.11.003","article-title":"MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo","volume":"22","author":"Fontan","year":"2012","journal-title":"Cancer Cell."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","article-title":"Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large b-cell lymphoma","volume":"34","author":"Crump","year":"2016","journal-title":"J Clin Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3109\/10428194.2015.1045898","article-title":"A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma","volume":"57","author":"Hainsworth","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009\u201308-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood."},{"key":"B107","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2015.10.005","article-title":"A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"54","author":"Flinn","year":"2016","journal-title":"Eur J Cancer."},{"key":"B108","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1073\/pnas.1008969108","article-title":"Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells","volume":"108","author":"Kloo","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B109","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80\u20136946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1200\/JCO.2017.35.15_suppl.7536","article-title":"Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"35","author":"Lenz","year":"2017","journal-title":"J Clin Oncol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.3324\/haematol.2017.172882","article-title":"CUDC-907 in relapsed\/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial","volume":"102","author":"Oki","year":"2017","journal-title":"Haematologica."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1158\/1078\u20130432.CCR-11\u20131407","article-title":"Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma","volume":"18","author":"Petrich","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.ajpath.2017.04.009","article-title":"AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma","volume":"187","author":"Wang","year":"2017","journal-title":"Am J Pathol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2016\u201312-758599","article-title":"Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL","volume":"130","author":"Erdmann","year":"2017","journal-title":"Blood."},{"key":"B116","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/bjh.13603","article-title":"Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma","volume":"171","author":"Oki","year":"2015","journal-title":"Br J Haematol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia."},{"key":"B119","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/leu.2015.99","article-title":"Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1","volume":"29","author":"Li","year":"2015","journal-title":"Leukemia."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1182\/blood-2018-06-859405","article-title":"Humanized Mcl-1 mice enable accurate pre-clinical evaluation of MCL-1 inhibitors destined for clinical use","volume":"132","author":"Brennan","year":"2018","journal-title":"Blood."},{"key":"B122","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365\u20132141.2011.08669.x","article-title":"Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas","volume":"153","author":"Brem","year":"2011","journal-title":"Br J Haematol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm0302\u2013282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J Clin Oncol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/leu.2011.28","article-title":"Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)","volume":"25","author":"Drakos","year":"2011","journal-title":"Leukemia."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1080\/10428194.2017.1376740","article-title":"Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma","volume":"59","author":"Herting","year":"2018","journal-title":"Leuk Lymphoma."},{"key":"B127","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nm.2282","article-title":"miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2016\u201311-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1535\u20137163.MCT-16\u20130555","article-title":"Combination of Ibrutinib and ABT-199 in diffuse large b-cell lymphoma and follicular lymphoma","volume":"16","author":"Kuo","year":"2017","journal-title":"Mol Cancer Ther."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood-2018\u201399-112988","article-title":"A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"132","author":"Younes","year":"2018","journal-title":"Blood."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T19:35:33Z","timestamp":1574192133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":133,"alternative-id":["10.3389\/fonc.2019.00107"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00107","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"article-number":"107"}}